Treatment decisions in multiple sclerosis — insights from real-world observational studies

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

(2016) Vilija G. Jokubaitis et al.   ANNALS OF NEUROLOGY

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Defining secondary progressive multiple sclerosis

(2016) Johannes Lorscheider et al.   BRAIN

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

(2016) T. Spelman et al.   EUROPEAN JOURNAL OF NEUROLOGY

Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study

(2016) A. Miclea et al.   JOURNAL OF NEUROLOGY

Immunomodulatory therapies delay disease progression in multiple sclerosis

(2016) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Disease-modifying therapies and infectious risks in multiple sclerosis

(2016) Alexander Winkelmann et al.   Nature Reviews Neurology

Assessing response to interferon-β in a multicenter dataset of patients with MS

(2016) Maria Pia Sormani et al.   NEUROLOGY

Recommendations for observational studies of comorbidity in multiple sclerosis

(2016) Ruth Ann Marrie et al.   NEUROLOGY

Comparative efficacy of fingolimod vs natalizumab

(2016) Laetitia Barbin et al.   NEUROLOGY

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

(2016) Tingting Zhang et al.   NEUROLOGY

Standardizing Patient Outcomes Measurement

(2016) Michael E. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrating Randomized Comparative Effectiveness Research with Patient Care

(2016) Louis D. Fiore et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory therapies delay disease progression in multiple sclerosis

(2016) Roberto Bergamaschi et al.   Multiple Sclerosis Journal

Observational data: Understanding the real MS world

(2016) Tomas Kalincik et al.   Multiple Sclerosis Journal

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

(2016) Damiano Baroncini et al.   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Registers of multiple sclerosis in Denmark

(2015) N. Koch-Henriksen et al.   ACTA NEUROLOGICA SCANDINAVICA

The Swedish MS registry - clinical support tool and scientific resource

(2015) J. Hillert et al.   ACTA NEUROLOGICA SCANDINAVICA

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

(2015) Tjalf Ziemssen et al.   BMC Neurology

Defining reliable disability outcomes in multiple sclerosis

(2015) Tomas Kalincik et al.   BRAIN

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

(2015) Mar Tintore et al.   BRAIN

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

(2015) Pietro Iaffaldano et al.   BRAIN

The rise of big clinical databases

(2015) J. A. Cook et al.   BRITISH JOURNAL OF SURGERY

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a

(2015) T. Uher et al.   EUROPEAN JOURNAL OF NEUROLOGY

Propensity score studies are unlikely to underestimate treatment effects in critical care medicine: a critical reanalysis

(2015) Georgios D. Kitsios   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator

(2015) Jacqueline Palace et al.   LANCET NEUROLOGY

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

(2015) T Frisell et al.   Multiple Sclerosis Journal

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Bayesian evidence synthesis for exploring generalizability of treatment effects: a case study of combining randomized and non-randomized results in diabetes

(2015) Pablo E. Verde et al.   STATISTICS IN MEDICINE

Data quality monitoring and performance metrics of a prospective, population-based observational study of maternal and newborn health in low resource settings

(2015) Shivaprasad S Goudar et al.   Reproductive Health

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

(2015) Anna He et al.   JAMA Neurology

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

(2015) T Frisell et al.   Multiple Sclerosis Journal

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Multivariate and Propensity Score Matching Software with Automated Balance Optimization: TheMatchingPackage forR

(2015) Jasjeet S. Sekhon   Journal of Statistical Software

Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort

(2014) Mohammad Ehsanul Karim et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Developing and validating risk prediction models in an individual participant data meta-analysis

(2014) Ikhlaaq Ahmed et al.   BMC Medical Research Methodology

The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials

(2014) Tjeerd-Pieter van Staa et al.   HEALTH TECHNOLOGY ASSESSMENT

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

(2014) H. Butzkueven et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

ACTRIMS-ECTRIMS MSBoston 2014: Poster Sessions 2

(2014)   Multiple Sclerosis Journal

Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients

(2014) Jordi Río et al.   Multiple Sclerosis Journal

Multiple sclerosis registries in Europe – results of a systematic survey

(2014) Peter Flachenecker et al.   Multiple Sclerosis Journal

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis

(2014) Tomas Kalincik et al.   Multiple Sclerosis Journal

Can we measure long-term treatment effects in multiple sclerosis?

(2014) Maria Pia Sormani et al.   Nature Reviews Neurology

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab

(2014) Marinella Clerico et al.   JAMA Neurology

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Big data: the next frontier for innovation in therapeutics and healthcare

(2014) Naiem T Issa et al.   Expert Review of Clinical Pharmacology

Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model

(2014) Martin Stangel et al.   Therapeutic Advances in Neurological Disorders

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Effectively Selecting a Target Population for a Future Comparative Study

(2013) Lihui Zhao et al.   JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION

Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis

(2013) Luca Prosperini et al.   Multiple Sclerosis Journal

Assessing treatment response to interferon- : Is there a role for MRI?

(2013) R. Dobson et al.   NEUROLOGY

A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis

(2013) Thomas P.A. Debray et al.   STATISTICS IN MEDICINE

Early predictors of non-response to interferon in multiple sclerosis

(2012) D. Horakova et al.   ACTA NEUROLOGICA SCANDINAVICA

The Norwegian Multiple Sclerosis Registry and Biobank

(2012) K.-M. Myhr et al.   ACTA NEUROLOGICA SCANDINAVICA

Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta

(2012) Robert A. Bermel et al.   ANNALS OF NEUROLOGY

Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States

(2012) Kenneth G. Saag et al.   Contemporary Clinical Trials

Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research

(2012) N. G. Weiskopf et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

(2012) H Tedeholm et al.   Multiple Sclerosis Journal

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

One-to-many propensity score matching in cohort studies

(2012) Jeremy A. Rassen et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A simulation study of finite-sample properties of marginal structural Cox proportional hazards models

(2012) Daniel Westreich et al.   STATISTICS IN MEDICINE

Simulating from marginal structural models with time-dependent confounding

(2012) W.G. Havercroft et al.   STATISTICS IN MEDICINE

Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic

(2012) Ebru Erbayat Altay et al.   JAMA Neurology

Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes

(2011) R. Philip Kinkel   ARCHIVES OF NEUROLOGY

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

(2009) M. Trojano et al.   ANNALS OF NEUROLOGY

High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data

(2009) Sebastian Schneeweiss et al.   EPIDEMIOLOGY

How to assess the external validity of therapeutic trials: a conceptual approach

(2009) O M Dekkers et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers

(2009) Kevin E. Thorpe et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

(2009) Ludwig Kappos et al.   LANCET NEUROLOGY

The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies

(2009) Peter C. Austin   MEDICAL DECISION MAKING

Measures in the first year of therapy predict the response to interferon β in MS

(2009) J Río et al.   Multiple Sclerosis Journal

Contribution of relapses to disability in multiple sclerosis

(2008) C. Hirst et al.   JOURNAL OF NEUROLOGY

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal